Viral Envelope Proteins - Genetics
Research News and Information

Sunday, November 22, 2009

Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression.

18 Oct 2009 Viruses have substantial value as vehicles for transporting transgenes into neurons. Each virus has its own set of attributes for addressing neuroscience-related questions. Here we review some of the advantages and limitations of herpes, ... Read more...

Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease.

13 Oct 2009 BACKGROUND:It is unknown whether specific viral polymorphisms affect in vivo therapeutic response in patients with cytomegalovirus (CMV) disease. Polymorphisms in the CMV glycoprotein B (gB) gene allow discrimination of 4 distinct genotypes ... Read more...

Structure of yellow fever virus envelope protein domain III.

6 Oct 2009 The structure of recombinant domain III of the envelope protein (rED3) of yellow fever virus (YFV), containing the major neutralization site, was determined using NMR spectroscopy. The amino acid sequence and structure of the YFV-rED3 shows ... Read more...

Latest indexed articles for 'Viral Envelope Proteins - Genetics'

These are the very latest articles for this heading:

• Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression. 18 Oct 2009
• Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. 13 Oct 2009
• Structure of yellow fever virus envelope protein domain III. 6 Oct 2009
• Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. 29 Sep 2009
• A duplex real-time reverse transcriptase polymerase chain reaction assay for the detection of California serogroup and Cache Valley viruses. 29 Sep 2009
• Bacterial cell surface display: a method for studying Japanese encephalitis virus pathogenicity. 30 Aug 2009
• Isolation and characterization of two phenotypically distinct dengue type-2 virus isolates from the same dengue hemorrhagic Fever patient. 30 Aug 2009
• Structural stability of hepatitis C virus envelope glycoprotein E1: effect of pH and dissociative detergents. 30 Aug 2009
• SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion. 27 Aug 2009
• Generation and characterization of JSRV envelope transgenic mice in FVB background. 17 Aug 2009
• Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. 16 Aug 2009
• Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. 13 Aug 2009
• An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. 5 Aug 2009
• Cross talk among the glycoproteins involved in herpes simplex virus entry and fusion: the interaction between gB and gH/gL does not necessarily require gD. 3 Aug 2009
• Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans. 3 Aug 2009
• Use of interfering RNAs targeted against feline herpesvirus 1 glycoprotein D for inhibition of feline herpesvirus 1 infection of feline kidney cells. 30 Jul 2009
• A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. 27 Jul 2009
• In silico prediction and ex vivo evaluation of potential T-cell epitopes in glycoproteins 4 and 5 and nucleocapsid protein of genotype-I (European) of porcine reproductive and respiratory syndrome virus. 27 Jul 2009
• Virological and epitope evolution of HCV infection from acute hepatitis C to subsequent episodes of HCV-related acute liver cell necrosis. 25 Jul 2009
• Mapping of the functional boundaries and secondary structure of the mouse mammary tumor virus Rem-responsive element. 22 Jul 2009

See a longer list of these articles.

Technical information about 'Viral Envelope Proteins'

Definition: Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.

Registry Number: 0

Descriptor UI: D014759

Alternative terms: Viral Envelope Proteins; Proteins, Viral Envelope; Virus Envelope Proteins; Envelope Proteins, Virus; Proteins, Virus Envelope; Envelope Proteins, Viral; Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus); Viral Envelope Proteins gp52; Viral Envelope Proteins gp70; Virus Peplomer Proteins; Peplomer Proteins, Virus; Proteins, Virus Peplomer; Bovine Leukemia Virus Glycoprotein gp51; Corona Virus Membrane Protein E1; Coronavirus gpE1; Coronavirus Peplomer Protein E1; Coronavirus Peplomer Protein E2 JHM; Hepatitis Virus (MHV) Glycoprotein E2; LaCrosse Virus Envelope Glycoprotein G1; Simian Sarcoma Virus Glycoprotein 70; Viral Envelope Glycoprotein gp55 (Friend Virus); Viral Envelope Proteins E1; Viral Envelope Proteins E2;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.776.964.970.880;

History Note: 84

Technical Notes: IM; coord with specific virus (IM); /drug eff /ultrastruct permitted